3--hydroxy-5--(4-isobutylpiperazinyl)benzoxazinorifamycin and sitafloxacin

3--hydroxy-5--(4-isobutylpiperazinyl)benzoxazinorifamycin has been researched along with sitafloxacin* in 1 studies

Other Studies

1 other study(ies) available for 3--hydroxy-5--(4-isobutylpiperazinyl)benzoxazinorifamycin and sitafloxacin

Article	Year
In-vitro activity of sitafloxacin (DU-6859a), either singly or in combination with rifampin analogs, against Mycobacterium leprae. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2003, Volume: 9, Issue:1 The in-vitro antibacterial activity of sitafloxacin (DU-6859a) against Mycobacterium leprae was evaluated and compared with those of ofloxacin, levofloxacin, and ciprofloxacin. Two biochemical indicators (intracellular ATP and uptake of [(3)H]-thymidine) were used to measure the in-vitro growth of M. leprae in Dhople-Hanks (DH) medium. Sitafloxacin was found to be more potent than the other three commonly used fluoroquinolones, with the minimum inhibitory concentration (MIC) against M. leprae being 0.1875 microg/ml and the action being bactericidal. The MICs of ofloxacin, levofloxacin, and ciprofloxacin were 1.5, 0.75, and 3.0 microg/ml, respectively. Similar to ofloxacin and levofloxacin, sitafloxacin also exhibited synergistic activity when combined with either rifabutin or KRM-1648, but not with rifampin. Thus, further studies on the incorporation of sitafloxacin in multidrug therapy regimens in treating leprosy patients are suggested. Topics: Animals; Anti-Infective Agents; Armadillos; Drug Synergism; Drug Therapy, Combination; Fluoroquinolones; Humans; Leprostatic Agents; Microbial Sensitivity Tests; Mycobacterium leprae; Rifabutin; Rifampin; Rifamycins	2003

Article

Year

In-vitro activity of sitafloxacin (DU-6859a), either singly or in combination with rifampin analogs, against Mycobacterium leprae.

Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2003, Volume: 9, Issue:1

The in-vitro antibacterial activity of sitafloxacin (DU-6859a) against Mycobacterium leprae was evaluated and compared with those of ofloxacin, levofloxacin, and ciprofloxacin. Two biochemical indicators (intracellular ATP and uptake of [(3)H]-thymidine) were used to measure the in-vitro growth of M. leprae in Dhople-Hanks (DH) medium. Sitafloxacin was found to be more potent than the other three commonly used fluoroquinolones, with the minimum inhibitory concentration (MIC) against M. leprae being 0.1875 microg/ml and the action being bactericidal. The MICs of ofloxacin, levofloxacin, and ciprofloxacin were 1.5, 0.75, and 3.0 microg/ml, respectively. Similar to ofloxacin and levofloxacin, sitafloxacin also exhibited synergistic activity when combined with either rifabutin or KRM-1648, but not with rifampin. Thus, further studies on the incorporation of sitafloxacin in multidrug therapy regimens in treating leprosy patients are suggested.

Topics: Animals; Anti-Infective Agents; Armadillos; Drug Synergism; Drug Therapy, Combination; Fluoroquinolones; Humans; Leprostatic Agents; Microbial Sensitivity Tests; Mycobacterium leprae; Rifabutin; Rifampin; Rifamycins

2003